Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Runimotamab |
| Trade Name | |
| Synonyms | BTRC4017A|RG6194|BTRC 4017A|BTRC-4017A|RG 6194|RG-6194 |
| Drug Descriptions |
Runimotamab (BTRC 4017A) is a bispecific antibody that targets both Erbb2 (Her2) and CD3, which may lead to CTL-dependent killing of Erbb2 (Her2)-expressing tumor cells (PMID: 30442682). |
| DrugClasses | CD3 Antibody 119 HER2 (ERBB2) Antibody 79 |
| CAS Registry Number | 2361325-98-4 |
| NCIT ID | C156705 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Runimotamab | Runimotamab | 0 | 1 |
| Runimotamab + Trastuzumab | Runimotamab Trastuzumab | 0 | 0 |